These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 7665724)

  • 1. Noninvasive assessment of mitoxantrone cardiotoxicity in relapsing remitting multiple sclerosis.
    De Castro S; Cartoni D; Millefiorini E; Funaro S; Gasperini C; Morino S; Tallarico D; Beni S
    J Clin Pharmacol; 1995 Jun; 35(6):627-32. PubMed ID: 7665724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis.
    Hamzehloo A; Etemadifar M
    Arch Iran Med; 2006 Apr; 9(2):111-4. PubMed ID: 16649351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac effects of mitoxanthrone therapy in patients with multiple sclerosis.
    Pastuszak Ż; Tomczykiewicz K; Piusińska-Macoch R; Stępień A
    Kardiol Pol; 2016; 74(4):380-4. PubMed ID: 26412472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the myocardial performance index for early detection of mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis.
    Pattoneri P; Pelà G; Montanari E; Pesci I; Moruzzi P; Borghetti A
    Eur J Echocardiogr; 2007 Mar; 8(2):144-50. PubMed ID: 16603413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
    Foo EC; Russell M; Lily O; Ford HL
    Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitoxantrone reduced disability in Iranian patients with multiple sclerosis.
    Hamzehloo A; Etemadifar M
    Arch Iran Med; 2007 Jan; 10(1):59-64. PubMed ID: 17198456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis: a tissue Doppler echocardiographic analysis.
    Pattoneri P; Sozzi F; Pelà G; Montanari E; Moruzzi P; Borghetti A; Cappellini MD
    Echocardiography; 2009 Apr; 26(4):397-402. PubMed ID: 19017314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.
    Hartung HP; Gonsette R; König N; Kwiecinski H; Guseo A; Morrissey SP; Krapf H; Zwingers T;
    Lancet; 2002 Dec 21-28; 360(9350):2018-25. PubMed ID: 12504397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis.
    Zingler VC; Nabauer M; Jahn K; Gross A; Hohlfeld R; Brandt T; Strupp M
    Eur Neurol; 2005; 54(1):28-33. PubMed ID: 16088176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-invasive functional and biochemical assessment of mitoxantrone cardiotoxicity in patients with multiple sclerosis.
    Spindler M; Weilbach F; Beer M; Sandstede J; Köstler H; Strotmann J; Voelker W; Hahn D; Ertl G; Gold R
    J Cardiovasc Pharmacol; 2003 Nov; 42(5):680-7. PubMed ID: 14576518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome.
    Millefiorini E; Gasperini C; Pozzilli C; D'Andrea F; Bastianello S; Trojano M; Morino S; Morra VB; Bozzao A; Calo' A; Bernini ML; Gambi D; Prencipe M
    J Neurol; 1997 Mar; 244(3):153-9. PubMed ID: 9050955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of the long term effect of mitoxantrone on neurological disability in patients with active multiple sclerosis].
    Mesaros S; Stojsavljević N; Dujmović I; Mandić E; Drulović J
    Srp Arh Celok Lek; 2004; 132(7-8):209-13. PubMed ID: 15615176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis.
    van de Wyngaert FA; Beguin C; D'Hooghe MB; Dooms G; Lissoir F; Carton H; Sindic CJ
    Acta Neurol Belg; 2001 Dec; 101(4):210-6. PubMed ID: 11851027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mitoxantrone].
    Pericot I; Montalban X
    Neurologia; 2003; 18(6):318-23. PubMed ID: 12838451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Acute heart failure in a patient treated by mitoxantrone for multiple sclerosis].
    Feuillet L; Guedj E; Eusebio A; Malikova I; Pelletier J; Mundler O; Ali Chérif A;
    Rev Neurol (Paris); 2003 Dec; 159(12):1169-72. PubMed ID: 14978418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.
    Goffette S; van Pesch V; Vanoverschelde JL; Morandini E; Sindic CJ
    J Neurol; 2005 Oct; 252(10):1217-22. PubMed ID: 15834643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.
    Rivera VM; Jeffery DR; Weinstock-Guttman B; Bock D; Dangond F
    BMC Neurol; 2013 Jul; 13():80. PubMed ID: 23841877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.
    Ramtahal J; Jacob A; Das K; Boggild M
    J Neurol; 2006 Sep; 253(9):1160-4. PubMed ID: 16990994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.